CD8A and neoplasm: Induction of a CD8+ anti-tumor response was associated with a reduction in relapse risk taking into account death as a competing risk (hazard ratio [HR], .30; 95% CI, .10 to .85; P = .02) and improved RFS (HR, .29; 95% CI, .10 to .83; P = .02) (Figure 1).